Crisnatol

Crisnatol
Clinical data
ATC code	none;
Identifiers
	IUPAC name 2-(Chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;
CAS Number	96389-68-3 ;
PubChem CID	57062;
ChemSpider	51449 ;
UNII	2J71UR51UE;
CompTox Dashboard (EPA)	DTXSID10242217 ;
Chemical and physical data
Formula	C23H23NO2
Molar mass	345.442 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CO)(CO)NCc1cc2c3ccccc3ccc2c4c1cccc4;
	InChI InChI=InChI=1S/C23H23NO2/c1-23(14-25,15-26)24-13-17-12-22-18-7-3-2-6-16(18)10-11-21(22)20-9-5-4-8-19(17)20/h2-12,24-26H,13-15H2,1H3 ; Key:SBRXTSOCZITGQG-UHFFFAOYSA-N ;

Crisnatol (BW-A770U) is an experimental anticancer agent.^[1] A Phase I clinical trial was published in 1999.^[2]

References

^ U.S. patent 4,719,046
^ Villalona-Calero MA, Petit T, Kuhn J, Cobb P, Kraynak M, Eckhardt SG, et al. (November 1999). "A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies". Clinical Cancer Research. 5 (11): 3369–78. PMID 10589747.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.